Magnesium for leg cramps: what the evidence shows

Magnesium is essential for normal muscle function. That does not mean a supplement prevents ordinary leg cramps.

By Volker Spitzer (www.sacapuntas-publishing.com) | Evidence reviewed through 26 August 2026 | 18-minute read

In 2015 and 2016, twenty family doctors across western Switzerland recruited patients over 50 with a history of leg cramps and had them keep a daily log for two weeks. A hundred and twenty-nine people finished the log every day, with complete follow-up, and two things stood out. First, the cramps themselves were mostly minor: a median of two per week, scored 0.7 out of 10 for severity, and lasting a median of 24 seconds. Second, a quarter of these patients were already taking magnesium when the study began, and half had tried some remedy for their cramps at some point. [1]

One dataset, and the whole problem in miniature: a complaint that is common, usually mild and self-limiting, met by a large population already treating it with a mineral.

Nor is the habit particular to Switzerland; up to 60 per cent of adults report having had nocturnal leg cramps at some point. [2] Advice to take magnesium comes from every side at once: packaging, pharmacists, physiotherapists, doctors short of better options, and patients passing the tip to one another. Few therapeutic beliefs command such matched confidence among consumers and health professionals alike.

A painful calf cramp at two in the morning practically begs for a simple explanation: the muscle must be short of magnesium, so replacing it should make the cramps stop. That story is biologically plausible and easy to explain, and that combination is largely why it has endured.

But the actual clinical question is narrower than the popular belief: in people who are not deficient, does extra magnesium prevent ordinary leg cramps? Where a genuine magnesium deficiency is present, it can cause muscle contractions and cramps, and treating it is good medicine. In otherwise healthy adults with recurrent night cramps, though, oral magnesium has not outperformed placebo, and the evidence behind that conclusion is firmer than the evidence behind most of the products sold alongside it.

SUMMARY FOR CONSUMERS Magnesium supplements are unlikely to make a meaningful difference for most otherwise healthy adults with ordinary night cramps. The trials that tested this used large doses, for weeks, and came back empty.Magnesium is essential for normal nerve and muscle function, and an authorised nutrient claim describes exactly that role. It does not show that extra magnesium treats cramps.The form of magnesium (citrate, oxide, bisglycinate) affects absorption and tolerance, but has not been shown to affect cramps.Evidence in pregnancy is genuinely unsettled: three reviews of the same four small trials reach different conclusions depending on which outcome they pool, and the most recent found a benefit. Worth trying, not proven. And for exercise-associated cramps, no randomised trial has tested magnesium at all.Confirmed or strongly suspected magnesium deficiency should be treated, with clinical guidance and attention to its underlying cause.Seek medical advice for symptoms that are persistent, severe or one-sided.

HOW TO READ THE NUMBERS IN THIS ARTICLE Confidence interval (CI). The range within which the true effect most likely falls. “0.18 fewer cramps per week (95% CI 0.84 fewer to 0.49 more)” means the best estimate is about a fifth of a cramp a week, and the data are compatible with anything from a small reduction to a slight increase. The interval usually matters more than the central estimate, since it shows what a study can and cannot rule out. Certainty rating. Systematic reviewers grade how much confidence a finding deserves, from very low to high, based on study quality, consistency between trials and precision. High certainty means further research is unlikely to change the answer. “No difference” is not “no evidence”. A single small trial that finds nothing leaves the question open. A pooled analysis of consistent trials, graded high certainty, has actually answered it, and most of the magnesium evidence in older adults is the second kind.

Why the mechanism predicts the result

Before getting to the trials, it is worth asking what a magnesium supplement actually does once it is inside the body; the answer shapes what should be expected from everything that follows.

About 99 per cent of the body’s magnesium is stored in bone and inside cells; less than one per cent circulates in serum, which happens to be the only compartment that gets measured. That is the legitimate reason magnesium status is difficult to assess, and it doubles as the illegitimate excuse for waving away any negative trial with “the participants were probably deficient anyway”.

What actually matters is whether swallowing magnesium raises the level in the tissue that cramps, and Weller and colleagues in Heidelberg tested precisely that. Athletes with low-normal serum magnesium received 500 mg of magnesium oxide daily for three weeks, and the team measured magnesium in calf muscle by nuclear magnetic resonance alongside serum and blood cells. Supplementation raised none of it: not serum, not any cellular compartment, not the calf muscle itself. The one thing it did raise was renal magnesium clearance, as the kidney simply disposed of the surplus. [4]

At Goethe University Frankfurt, Michael Behringer describes the same physiology from the opposite direction: the body maintains a large magnesium reserve, and when intake drops, it compensates by absorbing more efficiently through the gut, which is why a dietary shortfall rarely turns symptomatic in healthy people. [8]

There is also the question of where a cramp actually starts, and the electrophysiological evidence points to the alpha motor neuron rather than to the muscle fibre itself. Minetto and colleagues recorded motor unit discharge rates during cramps far above voluntary maximal rates, and demonstrated that cramps can be provoked and interrupted by altering afferent input from the tendon. [5] That points to a problem of spinal excitability, driven by fatigue, muscle shortening and heat. Sports medicine arrived at the same conclusion from the field: Schwellnus and colleagues compared distance runners who cramped during a race against those who did not, and found no association with serum electrolyte concentrations or hydration status. [6] Altered neuromuscular control has since overtaken electrolyte depletion as the leading model, with the caveat that the condition is multifactorial and no single mechanism has been established. [7]

Two caveats belong here before pulling this together. One tissue study cannot establish that oral magnesium never reaches muscle, and the review cited above says explicitly that cramping is multifactorial, with no single mechanism established. What the evidence does support is narrower, but still useful: that many idiopathic and exercise-associated cramps are driven mainly by altered neuromuscular control rather than by simple magnesium depletion, and that in people who are already replete, a supplement has not been shown to raise magnesium in muscle. Read that way, a null trial stops being a puzzle and becomes the expected result, which is the frame the trial evidence below should be read through.

One further piece of work deserves a flag, with the caveat that it remains unpublished. At Goethe University’s Institute of Sports Science, Christoph Skutschik has been using electrically induced cramps to establish each participant’s individual cramp threshold, then testing whether magnesium shifts it. Participants were assessed four times: on a single 250 mg dose, on a double 500 mg dose, and on placebo. According to his account of the results so far, neither dose had an effect. [8] Until this appears in a peer-reviewed journal it should be treated as a preliminary signal rather than an established finding. Even so, it is the first attempt to test the claim on the mechanism’s own terms, using a provoked cramp with a quantifiable threshold rather than a symptom diary. The same group is running a 16-week randomised trial of home-based neuromuscular electrical stimulation against magnesium supplementation, recruiting since early 2025. [9]

What the trials found

The single most informative overview is still the 2020 Cochrane review of magnesium for skeletal muscle cramps: 11 randomised trials and 735 participants in total, of whom 271 came from five trials of idiopathic cramps, mostly older adults with night-time symptoms whose mean ages ranged from 61.6 to 69.3 years. [3]

Three numbers do the work of the conclusion.

• By four weeks, magnesium had produced 0.18 fewer cramps per week than placebo (95% CI 0.84 fewer to 0.49 more; 5 studies, 307 participants; moderate certainty), an interval that spans a small reduction and a slight increase, and rules out any reduction a patient would actually notice.
• The per centage change from baseline came to minus 9.59 per cent (95% CI minus 23.14 to plus 3.97; 3 studies, 177 participants; moderate certainty).
• And the proportion of participants who achieved at least a 25 per cent reduction in cramp rate showed no difference at all: risk ratio 1.04 (95% CI 0.84 to 1.29; 3 studies, 177 participants), an outcome Cochrane graded high certainty.

Put plainly: about the same share of people improved by a quarter or more regardless of whether they took magnesium or placebo, and the reviewers considered that finding solid enough to earn a high-certainty grade.

That last grading is worth dwelling on, because it is rare. Most nutrition questions settle for “insufficient evidence”; this one settles on high-certainty evidence of no meaningful effect on the outcome patients care about most, with the trials agreeing with each other almost perfectly and virtually no disagreement between them. For the continuous measures, certainty was moderate rather than high, and the caveats are genuine: the trials were short, the samples modest, the participants mostly in their sixties. None of this should be stretched to younger people, to years of use, or to unusual cramp syndromes. Within its own population, though, it is about as settled as nutrition evidence gets.

It is worth stating the doses plainly, because the usual objection to these trials is that participants simply did not take enough magnesium. In fact, they took a great deal.

Frusso and colleagues, working with patients who had had at least six cramps in the preceding month, gave 900 mg of magnesium citrate twice daily for a month, then placebo for a month, in a crossover design with washout periods between. Mean cramps came to 11.8 on magnesium and 11.1 on placebo (p = 0.59). What the authors noticed, and named, was a period effect: everyone improved over time, regardless of which treatment came first, which they attributed to a combination of natural history, regression to the mean and a genuine placebo response. [10]

Roguin Maor and colleagues randomised 94 adults to four weeks of either 865 mg of magnesium oxide (about 520 mg of elemental magnesium) or placebo at bedtime. Weekly cramps dropped from 7.8 to 4.4 on magnesium, and from 8.5 to 5.5 on placebo, a between-group difference of just 0.38 cramps per week (p = 0.67), with no difference in pain, duration, sleep or quality of life. The trial was stopped early for futility. [11]

That dose is worth flagging: at roughly 520 mg of elemental magnesium a day, the trial delivered more than double the European tolerable upper intake level for supplemental magnesium, which sits at 250 mg. [17] If a dose that high changes nothing, “they did not take enough” is no longer available as an explanation.

The most instructive trial of the three is usually filed under “positive.” Roffe and colleagues gave magnesium citrate equivalent to 300 mg of elemental magnesium for six weeks, then placebo for six weeks. The counted cramps showed a trend towards fewer episodes on magnesium, but it did not reach conventional significance (p = 0.07), and severity and duration did not differ either. Yet when participants were simply asked whether the treatment had helped, 78 per cent said yes after magnesium against 54 per cent after placebo (p = 0.03). [12]

That gap between what patients counted and what patients felt is probably the single clearest explanation for why this belief survives. It does not mean people are imagining their improvement. Cramps fluctuate; treatment usually begins during a bad spell, and symptoms then tend to ease on their own regardless. Keeping a diary, expecting relief, and adjusting other habits at the same time all inflate the apparent response. A placebo-controlled trial exists precisely to strip those effects away from the supplement’s actual contribution, and when it does, most of the apparent benefit turns out to belong to the placebo side of the ledger.

What about the positive study?

Not every trial came back negative. Across seven Ukrainian centres, Barna and colleagues randomised 184 adults aged 45 and over to either 226 mg of magnesium oxide monohydrate or placebo, once daily at bedtime for 60 days; 175 completed the trial. Weekly cramp episodes fell by 3.4 on magnesium against 2.6 on placebo (p = 0.01), alongside shorter cramps and better reported sleep. [13]

That result deserves a careful reading rather than a dismissal, and three features belong alongside it in the assessment.

• Registration came retrospectively, and the trial was supported by an unrestricted grant from Naveh Pharma, the manufacturer of the tested formulation. Industry funding does not by itself invalidate a study, but it belongs in how the result is weighed.
• Cramp-associated pain showed no change (p = 0.954), even as frequency, duration and sleep quality all improved. That pattern is worth noting: an agent working through neuromuscular excitability might be expected to shift pain along with the other measures, not leave it untouched.
• The magnesium arm reported no adverse events at all, against four in the placebo arm, yet across the trials Cochrane pooled, gastrointestinal effects occurred in 11 to 37 per cent of magnesium recipients. [3] That is a substantial difference in reported tolerability, and it deserves weight when this trial is set against the others.

None of that proves the finding is wrong. What it does mean is that one sponsor-linked trial cannot overturn a high-certainty pooled null result, and should not be cited as if it had.

There is now a direct test of that claim. The 2026 review by Patil and colleagues pooled four adult trials of oral magnesium for nocturnal or persistent cramps, covering nearly 400 participants, the Ukrainian trial among them, and arrived at a mean difference of 0.42 fewer cramps per week (95% CI 1.15 fewer to 0.31 more, p = 0.26). Folding the positive trial into the analysis does not change the answer for adults. And because the same review reports a positive pooled result in pregnancy, its null result in adults is harder to write off as reviewer bias running in either direction. [23]

A 2026 trial adds a null result and a different possibility

In February 2026, Finnish investigators published a three-arm randomised trial of 121 adults aged 50 to 85, all with at least two leg cramps a week. For four weeks, participants used either knee-high medical compression stockings, magnesium hydrochloride, or placebo tablets daily, with the primary outcome measured at week 8. The tablet comparison was blinded; the stocking comparison, by its nature, could not be. [14]

Magnesium failed to beat placebo. The adjusted difference came to 0.20 fewer cramps per week (95% CI 1.49 fewer to 1.09 more, p = 0.929), an imprecise estimate that gives no hint of a useful effect.

Compression stockings fared better: 1.43 fewer cramps per week than placebo (95% CI 0.50 to 2.36 fewer, p = 0.001), along with fewer cramp-related awakenings and less reported pain. Four participants discontinued them because of skin reactions.

This is an emerging finding rather than a standard of care. A single modest, partly unblinded trial needs replication, and stockings are not suitable for everyone: people with suspected peripheral arterial disease, certain skin conditions, or severe sensory impairment among them. Anyone weighing stockings for recurrent cramps should confirm first that they are appropriate, especially where there is leg pain on walking, poor wound healing, altered sensation or known vascular disease. Caveats aside, the observation holds. Despite these limitations, compression stockings showed a benefit in this trial, whereas magnesium did not outperform placebo.

Where the evidence is clear and where it is not

The strongest conclusion in all of this concerns ordinary nocturnal cramps in otherwise healthy older adults; every other situation involves either weaker evidence or an altogether different clinical question.

Table 1. Magnesium for muscle cramps by clinical situation: best available evidence and proportionate conclusion.

Situation	Best available evidence	Proportionate conclusion
Idiopathic night cramps, mainly in older adults	Five trials, 271 participants, in the 2020 Cochrane review; high certainty for the 25 per cent responder outcome, moderate for continuous measures [3]	A clinically meaningful preventive effect is unlikely
Cramps in pregnancy	Four small trials, fewer than 400 women, analysed three ways. Cochrane 2020 declined to pool, certainty low to very low; a 2021 meta-analysis of the continuous outcome across three trials found no benefit; a 2026 meta-analysis of the responder outcome across all four found RR 1.35 (95% CI 1.05 to 1.74) favouring magnesium [21, 22, 23]	Unsettled. The answer depends on which outcome is pooled. Reasonable to try, given low risk and few alternatives, but not an established treatment. Discuss with a midwife or doctor
Exercise-associated cramps	The Cochrane search to September 2019 found no randomised magnesium trials; current reviews describe a multifactorial, neurally driven mechanism [3, 7]	Magnesium has not been shown to prevent them; no trial has tested it
Confirmed or clinically suspected magnesium deficiency	Established clinical and physiological evidence links marked deficiency with neuromuscular symptoms; drug-induced causes are well characterised [18, 19]	Treat the deficiency and its cause under clinical guidance
Muscle cramps during haemodialysis	Hypomagnesaemia in 10 to 20 per cent of patients; observational and pre-post studies suggest higher dialysate magnesium reduces cramps [20]	A plausible but unconfirmed effect; the lever is dialysate concentration, not an oral supplement
Cramps with liver, neurological or vascular disease	Evidence for oral magnesium is sparse and condition-specific [3]	Investigate and treat the underlying condition; do not generalise from ordinary night cramps

These conclusions do not transfer between situations. Evidence against routine supplementation for idiopathic night cramps says nothing about whether magnesium replacement helps in genuine deficiency. And by the same logic, the fact that deficiency can cause cramps does not mean deficiency is the cause of cramps in any given person.

Why the form of magnesium does not settle the question

Magnesium salts do differ from one another, genuinely. The difference just is not where the marketing puts it.

Organic formulations such as citrate do show higher short-term absorption than inorganic forms such as oxide. A 2021 systematic review, screening 433 records down to 14 comparative studies, found inorganic forms generally less bioavailable, yet the same authors concluded that with continued use, every form reviewed could maintain physiological magnesium levels in healthy people without a pre-existing deficit, while cautioning against assuming the same for older people, people with illness, or those starting from low levels. [15]

Bioavailability is a pharmacokinetic property: it describes how much of a substance the body actually takes up. Clinical efficacy is a different question entirely: does the product improve an outcome that matters? Better absorption can lend support to a mechanism, but it cannot stand in for a trial.

The most useful head-to-head comparison of magnesium salts in humans, tellingly, was not a cramp trial and should not be read as one. Schutten and colleagues randomised 164 overweight adults to 24 weeks of 450 mg of elemental magnesium daily, as citrate, oxide, sulfate, or placebo, with arterial stiffness and blood pressure as endpoints. Citrate raised 24-hour urinary magnesium excretion more than oxide or sulfate, confirming better absorption; plasma magnesium rose by roughly 0.04 mmol/L against placebo, with no difference between the three salts on that measure. None of the arms budged arterial stiffness or blood pressure. [16]

That trial says nothing directly about cramps, but what it does show is narrower and still relevant: across six months of dosing, a better-absorbed salt delivered more magnesium into the urine without changing the clinical result on the outcomes the study was built to measure. A real difference in a laboratory measure of absorption simply did not translate into a different effect at the endpoint.

For cramps specifically, the direct evidence is thinner still. The trials Cochrane pooled used several preparations and doses, including citrate and oxide, and none of them showed a consistent benefit in older adults [3]; no randomised trial has ever pitted one magnesium salt against another with cramps as the outcome. Magnesium bisglycinate may be better tolerated than magnesium oxide, but it is usually more expensive. Current evidence does not show that choosing one formulation over another reduces the frequency of cramps.

Dose, safety and interactions

The most common side effects of oral magnesium are diarrhoea, nausea and abdominal discomfort. Across the trials Cochrane included, gastrointestinal effects were common: 11 to 37 per cent of magnesium recipients against 10 to 14 per cent on placebo, and minor adverse events overall were more frequent on magnesium (RR 1.51, 95% CI 0.98 to 2.33), though serious adverse events and withdrawals did not differ. [3]

In Europe, the tolerable upper intake level is 250 mg a day of supplemental magnesium from readily dissociable salts and compounds such as magnesium oxide, a figure that excludes magnesium naturally present in food. It is a safety ceiling derived mainly from diarrhoea risk, not a target dose and not a threshold for effectiveness. [17] Clinically supervised treatment of a diagnosed deficiency is a different setting entirely, with different limits.

Anyone with impaired kidney function faces a higher risk of magnesium accumulation and toxicity, and supplements can also reduce the absorption of tetracycline and quinolone antibiotics and of oral bisphosphonates. [18] It is worth checking the elemental magnesium content on the label rather than the weight of the salt, counting any magnesium already taken as an antacid or laxative, and asking a pharmacist about interactions.

Deficiency is the real exception

Magnesium is essential to nerve, muscle and enzyme function, and marked deficiency can cause weakness, tremor, muscle contractions, cramps, seizures and abnormal heart rhythms. In a healthy person, though, symptomatic deficiency from diet alone is uncommon, because the kidneys conserve magnesium as stores fall. [18]

Risk climbs when absorption is impaired or losses increase. Bosman and colleagues mapped out the shared mechanisms behind genetic and drug-induced hypomagnesaemia, and the drug list is the part worth remembering: proton pump inhibitors, loop and thiazide diuretics, calcineurin inhibitors and some chemotherapy agents, alongside chronic diarrhoea and malabsorption, alcohol dependence and poorly controlled diabetes. [19]

Haemodialysis deserves its own mention, because it is the one clinical setting with a genuinely plausible magnesium-cramp dose-response story. Hypomagnesaemia affects 10 to 20 per cent of people on haemodialysis, and cramping consistently ranks among their top research priorities. Observational and pre-post interventional work suggests that raising the dialysate magnesium concentration raises serum magnesium, may reduce cramp frequency and severity, and appears well tolerated, though the evidence remains limited and larger randomised trials are still needed. Here the lever is the dialysate, not an oral capsule. [20]

This is where cause and association need to stay separate. A cramp in someone taking a diuretic is not proof that low magnesium caused it; it is a prompt for a clinician to review symptoms, medicines, diet and kidney function, and to test where that is warranted.

Serum magnesium testing is useful but imperfect, since most of the body’s magnesium sits in bone and cells; a normal result does not precisely describe every tissue store. That is a reason to read the test alongside clinical context, not a reason to assume everyone with cramps is deficient. [18]

Pregnancy: three reviews, one small evidence base, no agreement

Pregnancy is where this evidence base genuinely pulls in different directions, and the disagreement is worth walking through carefully, because it is not a disagreement about new data at all.

The 2020 Cochrane review of interventions for leg cramps in pregnancy drew on eight small studies covering 576 women, and its findings on magnesium against placebo pulled in different directions: one trial found women more likely to report never having cramps afterwards (RR 5.66, 95% CI 1.35 to 23.68), another found little or no difference in cramp frequency (MD 1.80, 95% CI minus 1.32 to 4.92), and the pain results split similarly. The reviewers could not pool any of it, because every trial measured cramps differently, and graded the overall evidence low to very low certainty. That grading, notably, came mainly from small samples and imprecision rather than from poor conduct; several of the trials, Nygaard and Supakatisant among them, were rated low risk of bias on most domains. [21]

The 2021 meta-analysis by Liu and colleagues did pool the data, drawing on four randomised trials and 332 women, and found no reduction in cramp frequency after treatment (pooled difference 0.47 fewer, 95% CI 1.14 fewer to 0.20 more, p = 0.167) and no improvement in recovery from cramps (odds ratio 0.47, 95% CI 0.14 to 1.52). Its conclusion: oral magnesium is not effective for leg cramps in pregnancy. One methodological detail matters here: only three of the four trials reported each outcome, so every pooled estimate rests on three studies rather than four, and the frequency analysis specifically omits Supakatisant, the trial with the clearest positive frequency result. [22]

In 2026, Patil and colleagues reached the opposite conclusion in a systematic review and meta-analysis conducted according to a prespecified methodology. The review was registered in PROSPERO, followed PRISMA guidance, searched PubMed, Embase and CENTRAL from January 1995 to August 2025, assessed risk of bias with RoB 2, and pooled results using random-effects models. Thirteen trials met the criteria across muscle pain syndromes; the stated purpose was to establish whether electrolyte modulation might be worth testing in temporomandibular disorder. [23]

For pregnancy specifically, they pooled all four trials, roughly 364 women, using the proportion achieving at least a 50 per cent reduction in cramp frequency, and arrived at a pooled risk ratio of 1.35 (95% CI 1.05 to 1.74, p = 0.02) favouring magnesium. Applying RoB 2, they judged most of the pregnancy trials to be at low risk, with adequate randomisation and blinding. Their conclusion is that magnesium supplementation “benefits pregnancy-related cramps but shows inconsistent effects in other populations”. [23]

Three reviews, three different answers, and underneath the two that pooled, the same four trials: Dahle in Sweden, Nygaard in Norway, Supakatisant in Thailand, Araujo in Brazil. No new randomised evidence appeared between 2020 and 2026. What actually differs between the reviews is which number each team chose to combine, and which studies made it into each analysis.

• Cochrane pooled nothing at all, since the four trials measured cramps in incompatible ways. Only Supakatisant actually reported the proportion of women improving by at least half (RR 1.42, 95% CI 1.09 to 1.86, 86 women).
• Liu pooled a continuous measure, cramps per week after treatment, across three of the four trials, leaving out the one with the clearest positive frequency result, and that estimate came back null.
• Patil pooled a responder measure across all four trials, even though only one of them had actually reported its results in that form, and that estimate came back positive.

So the disagreement is not really about magnesium at all; it is about what a reviewer does with four small trials that each answered a slightly different question. One team declined to combine them; one combined three on a continuous scale; one combined all four on a responder scale that three of them had not actually reported. Every one of those choices is defensible, and every one produces a different headline.

Two further details belong in this picture. Three of the four trials were never preregistered. And in Nygaard, one author had helped develop the magnesium tablet being tested and received payment from its manufacturer, a conflict both Cochrane and Liu flag explicitly. Anyone who considers the funding behind the Ukrainian adult trial relevant should hold this one to the same standard.

This is exactly the problem Cochrane identified at the close of its own review: without an agreed way of measuring a cramp, the same evidence can support different summaries depending on who is handling it. The practical conclusion is a call for a core outcome set, and it still has not been answered.

Where that leaves a clinician is genuinely unresolved, neither confidently positive nor confidently negative. A real pooled estimate favours magnesium, and it should not be dismissed simply because it turned up in a dental journal; a real pooled estimate also shows nothing. Both rest on the same four trials, fewer than 400 women in total, none of which was ever designed to be combined with the others. Given the low risk of oral magnesium at ordinary doses and the shortage of alternatives in pregnancy, an empirical trial in an individual patient remains reasonable, and the 2026 analysis lends that a bit more support than it had before. It stays a treatment worth trying, not one that has been shown to work.

Pregnant women experiencing frequent or troublesome cramps should discuss both the symptoms and any supplement dose with a midwife, pharmacist or doctor. The question worth asking is not only whether magnesium might help, but whether some other symptom or cause needs attention.

Exercise-associated cramps: no trials at all

Exercise-associated muscle cramps get routinely blamed on sweat, dehydration or lost minerals. Those factors can matter in some circumstances, prolonged exertion in heat especially, but they do not explain why one person cramps and another does not.

The striking fact here is an absence. Cochrane’s search, current to September 2019, turned up no randomised controlled trials of magnesium for exercise-associated cramps at all. [3] Not negative trials: none. This is also the population most prominently targeted by marketing, despite having the least direct evidence to support magnesium use.

A plausible role for nerves, fatigue or fluid balance is mechanistic evidence, not proof that a magnesium tablet keeps runners or cyclists from cramping. Athletes should still replace fluids and sodium in proportion to conditions and losses, for performance and safety reasons that stand entirely on their own, but magnesium should not be sold as a proven anti-cramp measure. The current model points elsewhere: building fatigue resistance through graded training, avoiding unaccustomed loads, and managing heat and fluid balance. [7]

What the labels are allowed to say

Almost every magnesium cramp claim made in Europe traces back to one of two regulatory texts, and both are narrower than the marketing built on top of them.

The European Food Safety Authority, EFSA, is the EU’s independent scientific risk-assessment agency, and its job is to evaluate the evidence behind proposed food health claims; the European Commission and EU Member States then decide which claims may actually be used, and under what conditions. In a 2009 scientific opinion, EFSA’s Panel on Dietetic Products, Nutrition and Allergies concluded that a cause-and-effect relationship had been established between dietary magnesium intake and normal neurotransmission and muscle contraction, including contraction of the heart muscle. [24] That opinion is why EU law authorises the wording “Magnesium contributes to normal muscle function” on foods that meet the conditions for a source of magnesium. [25]

That is strong evidence for an essential physiological role, not evidence that a supplement prevents or treats cramps. EFSA assessed a maintenance claim for the general population, not a therapeutic one, and the opinion never tested supplemental magnesium against placebo in people with nocturnal, pregnancy-related or exercise-associated cramps. Whether extra magnesium eases those symptoms is a separate clinical question, one answered by trials that actually count cramps, and those trials are, on the whole, negative or uncertain.

The second text is more pointed, and it is German. Magnesium products licensed in Germany as medicinal products rather than sold as food supplements carry an approved indication that names cramps explicitly and then fences them in. Magnesiocard, a magnesium aspartate hydrochloride preparation, is authorised for the treatment of magnesium deficiency states requiring therapy and, specifically, “bei nachgewiesenem Magnesiummangel, wenn er Ursache für Störungen der Muskeltätigkeit (neuromuskuläre Störungen, Wadenkrämpfe) ist”: in proven magnesium deficiency, when that deficiency is the cause of the neuromuscular disturbance. [26] The indication therefore depends on two essential conditions: magnesium deficiency must be confirmed, and it must be the cause of the neuromuscular symptoms.

A regulator that reviewed this evidence drew precisely the line the trials support, and put it on the box. The gap between that narrow indication and the way magnesium actually gets recommended is not a scientific dispute at all. It is a communication failure.

What can you do instead?

Most leg cramps are brief and harmless, even though the muscle can stay sore afterwards. For an acute cramp, NHS consumer guidance recommends gently stretching and massaging the affected muscle; standing up and putting weight through the leg can also help. [27]

For prevention specifically, the evidence is limited rather than impressive.

• Try regular calf stretching. A randomised trial of 80 adults over 55 found fewer and less painful night cramps after six weeks of nightly calf-and-hamstring stretching, taking under three minutes a day. [28] A 2021 Cochrane review of non-drug therapies rated the evidence low to very low certainty across three trials and 201 participants, and noted that calf stretching alone showed little to no difference against sham stretching. [29] Even so, stretching is cheap and low-risk within a comfortable range.
• Review possible triggers. A clinician or pharmacist can check whether symptoms started after a medicine change, and whether a circulatory, neurological, metabolic or musculoskeletal problem could be involved. Do not stop a prescribed medicine on your own.
• Correct any genuine fluid or nutritional deficit. That makes sense when a deficit actually exists; it is not the same as assuming every cramp signals dehydration or magnesium deficiency.
• Treat the right condition. Restless legs syndrome, peripheral neuropathy, claudication, dystonia and muscle pain are all frequently mistaken for cramps, and each needs its own assessment.

One unusual option carries better mechanistic support than its reputation would suggest. Miller and colleagues found that a small volume of pickle brine shortened electrically induced cramps by about 37 per cent compared with water, with relief arriving in roughly 85 seconds, far too fast for any electrolyte to have actually been absorbed. The proposed mechanism is receptor activation in the mouth and throat that reflexively inhibits the overactive motor neurons. [30] The evidence is early and the effect is not universal, but at least it targets the organ where the cramp actually originates.

Quinine can modestly reduce night cramps, but UK regulators advise against routine use, since the benefit is limited and the uncommon serious harms include thrombocytopenia, alongside cardiac effects and drug interactions. [31] It is a prescribing decision reserved for selected patients whose sleep is regularly disrupted, once treatable causes and non-drug measures have been considered, not a substitute for a supplement.

When to seek medical advice

See a GP or other qualified clinician if cramps regularly disturb sleep, last longer than 10 minutes, or come with numbness or swelling. [27] Earlier assessment makes sense when cramps are new and persistent, affect only one leg with swelling or a change in the skin, follow a medicine change, or come with weakness, loss of sensation, fever, severe pain or difficulty walking.

New, unexplained swelling, redness or warmth on one side needs urgent medical attention. Chest pain, sudden breathlessness, coughing up blood or collapse can signal a pulmonary embolism and call for emergency help. [32] None of these belongs to a simple cramp.

Conclusion

Magnesium’s reputation as a general remedy for cramps has outrun the evidence supporting it. In people who are already replete, oral supplementation has not been shown to raise magnesium levels in muscle. For both idiopathic and exercise-associated cramps, the leading model is altered neuromuscular control rather than simple magnesium depletion, though the condition remains multifactorial and the mechanism is not fully settled. And in trials that actually counted cramps in older adults, at doses above the European safety ceiling, sustained over weeks, magnesium has not beaten placebo, with high-certainty evidence behind the outcome that matters most to patients.

That conclusion still needs precise scoping, because scope is exactly where this topic goes wrong in both directions. Magnesium replacement is appropriate when deficiency is established or strongly suspected, and it is worth knowing the drug and disease contexts that cause it. Pregnancy remains a genuinely open question, on which three reviews of the same four trials disagree depending on which outcome they pool, and exercise- and disease-related cramps are largely untested rather than disproven. The German medicines regulator, meanwhile, already draws a defensible line on its own packaging: proven deficiency, when deficiency is the cause.

For everyone else, a review of current medicines, three minutes of stretching before bed, attention to the conditions that mimic cramps, and awareness of the warning signs make more defensible first steps than picking between supplement formulations.

References

1. Sebo P, Haller D, Cerutti B, Maisonneuve H. A prospective observational study of the main features of nocturnal leg cramps in primary care. Swiss Med Wkly. 2019;149:w20048. doi:10.4414/smw.2019.20048
2. Allen RE, Kirby KA. Nocturnal leg cramps. Am Fam Physician. 2012;86(4):350-355. aafp.org
3. Garrison SR, Korownyk CS, Kolber MR, et al. Magnesium for skeletal muscle cramps. Cochrane Database Syst Rev. 2020;9(9):CD009402. doi: 10.1002/14651858.CD009402.pub3
4. Weller E, Bachert P, Meinck HM, Friedmann B, Bärtsch P, Mairbäurl H. Lack of effect of oral Mg-supplementation on Mg in serum, blood cells, and calf muscle. Med Sci Sports Exerc. 1998;30(11):1584-1591. doi:10.1097/00005768-199811000-00005
5. Minetto MA, Holobar A, Botter A, Farina D. Origin and development of muscle cramps. Exerc Sport Sci Rev. 2013;41(1):3-10. doi:10.1097/JES.0b013e3182724817
6. Schwellnus MP, Nicol J, Laubscher R, Noakes TD. Serum electrolyte concentrations and hydration status are not associated with exercise associated muscle cramping (EAMC) in distance runners. Br J Sports Med. 2004;38(4):488-492. doi:10.1136/bjsm.2003.007021
7. Miller KC, McDermott BP, Yeargin SW, Fiol A, Schwellnus MP. An evidence-based review of the pathophysiology, treatment, and prevention of exercise-associated muscle cramps. J Athl Train. 2022;57(1):5-15. doi:10.4085/1062-6050-0696.20
8. Sachs C, Rathfelder N. Wie wirksam ist Magnesium wirklich? SWR Wissen. First published 5 July 2023, updated 10 June 2026. Interviews with Prof. Michael Behringer and Christoph Skutschik, Institut für Sportwissenschaften, Goethe-Universität Frankfurt. Reports preliminary, as yet unpublished cramp-threshold results at 250 mg and 500 mg magnesium.
9. Goethe-Universität Frankfurt am Main. Suffering from (nocturnal) muscle cramps? Seeking participants for new sports science study. Press release, 17 January 2025. idw-online.de
10. Frusso R, Zárate M, Augustovski F, Rubinstein A. Magnesium for the treatment of nocturnal leg cramps: a crossover randomized trial. J Fam Pract. 1999;48(11):868-871. PMID 10907623
11. Roguin Maor N, Alperin M, Shturman E, et al. Effect of magnesium oxide supplementation on nocturnal leg cramps: a randomized clinical trial. JAMA Intern Med. 2017;177(5):617-623. doi:10.1001/jamainternmed.2016.9261
12. Roffe C, Sills S, Crome P, Jones P. Randomised, cross-over, placebo controlled trial of magnesium citrate in the treatment of chronic persistent leg cramps. Med Sci Monit. 2002;8(5):CR326-CR330. PMID 12011773
13. Barna O, Lohoida P, Holovchenko Y, et al. A randomized, double-blind, placebo-controlled, multicenter study assessing the efficacy of magnesium oxide monohydrate in the treatment of nocturnal leg cramps. Nutr J. 2021;20:90. doi:10.1186/s12937-021-00747-9
14. Kuusipalo A, Laitila J, Lehtonen E, et al. Secondary prevention of leg cramps using compression stockings or magnesium supplements: a three-arm randomized clinical trial. Trials. 2026;27:216. doi:10.1186/s13063-025-09370-z
15. Pardo MR, Garicano Vilar E, San Mauro Martín I, Camina Martín MA. Bioavailability of magnesium food supplements: a systematic review. Nutrition. 2021;89:111294. doi:10.1016/j.nut.2021.111294
16. Schutten JC, Joris PJ, Groendijk I, et al. Effects of magnesium citrate, magnesium oxide, and magnesium sulfate supplementation on arterial stiffness: a randomized, double-blind, placebo-controlled intervention trial. J Am Heart Assoc. 2022;11(6):e021783. doi:10.1161/JAHA.121.021783
17. Scientific Committee on Food. Opinion on the tolerable upper intake level of magnesium. European Commission; 2001. SCF/CS/NUT/UPPLEV/54 Final. europa.eu
18. US National Institutes of Health, Office of Dietary Supplements. Magnesium: fact sheet for health professionals. Updated 6 January 2026. ods.od.nih.gov
19. Bosman W, Hoenderop JGJ, de Baaij JHF. Genetic and drug-induced hypomagnesemia: different cause, same mechanism. Proc Nutr Soc. 2021;80(3):327-338. doi:10.1017/S0029665121000926
20. Varghese A, Lacson E Jr, Sontrop JM, et al. A higher concentration of dialysate magnesium to reduce the frequency of muscle cramps: a narrative review. Can J Kidney Health Dis. 2020;7:2054358120964078. doi:10.1177/2054358120964078
21. Luo L, Zhou K, Zhang J, Xu L, Yin W. Interventions for leg cramps in pregnancy. Cochrane Database Syst Rev. 2020;12(12):CD010655. doi:10.1002/14651858.CD010655.pub3
22. Liu J, Song G, Zhao G, Meng T. Effect of oral magnesium supplementation for relieving leg cramps during pregnancy: a meta-analysis of randomized controlled trials. Taiwan J Obstet Gynecol. 2021;60(4):609-614. doi:10.1016/j.tjog.2021.05.006
23. Patil S, Falkowski A, Venkataiah VS, Bhandi S, Licari FW, Patil AG. The role of electrolytes in muscle pain syndromes: a systematic review and meta-analysis with implications for temporomandibular disorder. Int Dent J. 2026;76(3):109488. PROSPERO CRD420251120631. doi:10.1016/j.identj.2026.109488
24. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). Scientific opinion on the substantiation of health claims related to magnesium pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA Journal. 2009;7(9):1216. doi:10.2903/j.efsa.2009.1216
25. European Commission. Commission Regulation (EU) No 432/2012 establishing a list of permitted health claims made on foods. Official Journal of the European Union. 2012;L136:1-40. eur-lex.europa.eu
26. Verla-Pharm Arzneimittel. Magnesiocard 2,5 mmol Filmtabletten: Gebrauchsinformation, Anwendungsgebiete. Accessed 26 August 2026. patienteninfo-service.de
27. NHS. Leg cramps. Accessed 26 August 2026. nhs.uk
28. Hallegraeff JM, van der Schans CP, de Ruiter R, de Greef MHG. Stretching before sleep reduces the frequency and severity of nocturnal leg cramps in older adults: a randomised trial. J Physiother. 2012;58(1):17-22. doi:10.1016/S1836-9553(12)70068-1
29. Hawke F, Sadler SG, Katzberg HD, Pourkazemi F, Chuter V, Burns J. Non-drug therapies for the secondary prevention of lower limb muscle cramps. Cochrane Database Syst Rev. 2021;5(5):CD008496. doi:10.1002/14651858.CD008496.pub3
30. Miller KC, Mack GW, Knight KL, et al. Reflex inhibition of electrically induced muscle cramps in hypohydrated humans. Med Sci Sports Exerc. 2010;42(5):953-961. doi:10.1249/MSS.0b013e3181c0647e
31. Medicines and Healthcare products Regulatory Agency. Quinine: not to be used routinely for nocturnal leg cramps. Drug Safety Update. 2010;3(11):3; page updated 11 December 2014. gov.uk
32. NHS. Pulmonary embolism. Accessed 26 August 2026. nhs.uk

Keep the review

Download the complete evidence review

PDF English ↓ PDF Deutsch ↓